Supplementary Table S3 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table 3. Key Tumor Characteristics (AR Resistance Variants, AVPC Molecular Features, and GR Status) of Patients in Dose Expansion
Authors: Wassim Abida, Andrew W. Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R. Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Christopher J. Logothetis, Michael J. Morris
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392854084